UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(I. R. S. Employer Identification No.) |
(Address of principal executive offices, including ZIP code)
(
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 2.02 | Results of Operations and Financial Condition. |
On August 6, 2021, Twist Bioscience Corporation (the “Company”) issued a press release announcing its financial results for the third quarter ended June 30, 2021. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information furnished in this Item 2.02, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. |
Description | |
| 99.1 | Press release dated August 6, 2021 titled “Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results.” | |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: August 6, 2021 | Twist Bioscience Corporation |
| /s/ Emily M. Leproust | |
| Emily M. Leproust President and Chief Executive Officer |
Exhibit 99.1
Twist Bioscience Reports Third Quarter Fiscal 2021 Financial Results
-- Revenue Growth of 65% over Fiscal 2020 Third Quarter --
-- Order Growth of 58% Year over Year --
-- Gross Margin of 40% for the Quarter --
SOUTH SAN FRANCISCO, Calif. – August 6, 2021 – Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the third quarter of fiscal 2021 ended June 30, 2021.
“It is an exciting time to be at the forefront of synthetic biology,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “The opportunity continues to expand as our customers pursue new and innovative solutions to life’s grand challenges in the areas of healthcare, sustainable chemicals, food, agriculture and more. Together with the promise of future applications, we continue to deliver solid revenue growth and extend our proprietary silicon-based DNA synthesis platform to new markets ripe for disruption.”
FISCAL 2021 THIRD QUARTER FINANCIAL RESULTS
| · | Orders: Total orders received for the third quarter of fiscal 2021 were $39.1 million, compared to $24.7 million for the same period of fiscal 2020. | |
| · | Revenue: Total revenues were $35.0 million for the third quarter of fiscal 2021 compared to $21.2 million for the same period of fiscal 2020. | |
| · | Cost of Revenues: Cost of revenues for the third quarter of fiscal 2021 was $20.9 million compared to $16.5 million for the same period of fiscal 2020. | |
| · | Research and Development Expenses: Research and development expenses for the third quarter of fiscal 2021 were $19.8 million compared to $10.4 million for the same period of fiscal 2020. | |
| · | Selling, General and Administrative Expenses: Selling, general and administrative expenses for the third quarter of fiscal 2021 were $34.5 million compared to $22.5 million for the same period of fiscal 2020. | |
| · | Net Loss: Net loss for the third quarter of fiscal 2021 was $40.0 million, or $0.82 per share, compared to $28.2 million, or $0.67 per share, for the third quarter of fiscal 2020. | |
| · | Cash Position: As of June 30, 2021, the company had $519.4 million in cash, cash equivalents and short-term investments. |
“Our gross margin was 40% for the quarter, reflecting the higher contribution margin and mix of NGS tools. We are raising our revenue guidance based on continued strength across our business,” commented Jim Thorburn, CFO of Twist.
Fiscal Third Quarter 2021 and Recent Highlights
| · | Shipped products to approximately 1,800 customers in the third quarter of fiscal 2021 versus approximately 1,400 in the same period of fiscal 2020. |
| · | Shipped 107,000 genes during the third quarter versus 83,000 in the same period of fiscal 2020. |
| · | Supported the Engineering Biology Research Consortium (EBRC) and its Statement of Ethics in Engineering Biology Research. A companion paper, titled “Guiding ethical principles in engineering biology research,” to contextualize the purpose and principles behind the Statement has also now been published in ACS Synthetic Biology. |
| · | Acquired iGenomX, a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows. The acquisition is expected to enhance Twist’s capabilities to support multiplex sequencing preparations across multiple markets and to accelerate Twist’s conversion of customers from static microarray platforms to genotyping by sequencing workflows. |
| · | Launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, a robust all-in-one solution designed to maximize accuracy and efficiency in library construction and amplification when conducting next-generation sequencing (NGS). The kit is optimized for challenging NGS applications including liquid biopsy, somatic variant testing and genome-wide association studies. In addition, the kit excels in preparing samples where the amount of sample input DNA is either very limited or heavily degraded, as in the case of many banked oncology samples. |
| · | Announced a collaboration with Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary of Regeneron, for the production of a custom next-generation sequencing (NGS) population genetics genotyping assay. Arising from a need to incorporate the genetic differences of global populations, this assay is designed to gain new insights into disease mechanisms, identify novel drug targets, and accelerate drug discovery and development. Twist markets the assay as the Twist Diversity SNP Panel, and makes the content available to researchers globally for their population genomics studies. |
| · | Began shipping synthetic RNA reference controls for the SARS-CoV-2 Delta (B.1.617.2), Kappa (B.1.617.1) and B.1.617.3 variants first identified in India and spreading rapidly worldwide. |
| · | The DNA Data Storage Alliance, of which we are a participating member, published its first white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” |
| · | Inclusion in the State Street Global Advisors Gender Diversity Index (SHE). |
| · | Appointed Melissa Starovasnik, Ph.D., formerly vice president, protein sciences and head of large molecule drug discovery at Genentech, Inc., to the Board of Directors. |
Updated Fiscal 2021 Financial Guidance
The following statements are based on Twist’s current expectations for fiscal 2021. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below. Twist does not plan to update, nor does it undertake any obligation to update, this outlook in the future.
For the full fiscal year 2021, Twist provided the following updated financial guidance:
| • | Increasing revenue guidance, which is now expected to be in the range of $129 million to $132 million |
| ○ | Synbio revenue including Ginkgo Bioworks is expected to be in the range of $54 to $56 million |
| ○ | NGS revenue is estimated to be in the range of $69 to $70 million |
| ○ | Biopharma revenue is estimated to be approximately $6 million |
| • | Gross margin is expected to be 38% to 40% for fiscal 2021 |
| • | Operating expenses including R&D and SG&A are expected to be $200 million for the year |
| • | Net loss is expected to be approximately $150 million, reflecting our increased investments in our commercial organization and research and development activities |
| ○ | R&D is expected to be approximately $70 million |
| ○ | Stock-based compensation is expected to be approximately $37 million |
| ○ | Depreciation is expected to be $10 million |
| ○ | Capital expenditures are expected to be $40 million, including expansion into “Factory of the Future” |
Conference Call Information
The company plans to hold a conference call and live audio webcast for analysts and investors today at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company’s business. The call can be accessed by dialing (866) 688-0947 (domestic) or (409) 217-8781 (international) and refer to the conference ID 3485949. A telephonic replay of the conference call will be available beginning approximately four hours after the call through August 13, 2021 and may be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international). The replay conference ID is 3485949. The webcast replay will be available for two weeks.
Given the circumstances globally, it is recommended to dial-in at most 15 to 20 minutes prior to the call start to reduce waiting times. If a participant will be listen-only, they are encouraged to listen via the webcast on Twist’s investor page.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation the statements under “Updated Fiscal 2021 Financial Guidance,” the quotations of our Chief Executive Officer regarding Twist Bioscience’s opportunity, among other things, and the statements regarding the expected impact of the acquisition of iGenomX, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on May 7, 2021 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
CONTACT:
Angela Bitting
SVP, Corporate Affairs
925- 202-6211
abitting@twistbioscience.com
# # #
Twist Bioscience Corporation
Condensed Consolidated Statements of Operations
(Unaudited)
(in thousands)
| Three months ended June 30, | Nine months ended June 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenues | $ | 35,018 | $ | 21,207 | $ | 94,382 | $ | 57,668 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of revenues | 20,933 | 16,472 | 58,123 | 43,829 | ||||||||||||
| Research and development | 19,838 | 10,444 | 49,629 | 31,369 | ||||||||||||
| Selling, general and administrative | 34,478 | 22,487 | 97,658 | 76,082 | ||||||||||||
| Change in fair value of acquisition consideration | 1,887 | - | 1,887 | - | ||||||||||||
| Litigation settlement | - | - | - | 22,500 | ||||||||||||
| Total operating expenses | $ | 77,136 | $ | 49,403 | $ | 207,297 | $ | 173,780 | ||||||||
| Loss from operations | $ | (42,118 | ) | $ | (28,196 | ) | $ | (112,915 | ) | $ | (116,112 | ) | ||||
| Interest income | 86 | 247 | 377 | 1,388 | ||||||||||||
| Interest expense | (70 | ) | (181 | ) | (284 | ) | (644 | ) | ||||||||
| Other income (expense), net | (312 | ) | (56 | ) | (305 | ) | (125 | ) | ||||||||
| Provision for income taxes | 2,377 | (21 | ) | 2,271 | (120 | ) | ||||||||||
| Net loss attributable to common stockholders | $ | (40,037 | ) | $ | (28,207 | ) | $ | (110,856 | ) | $ | (115,613 | ) | ||||
| Net loss per common share, basic and diluted | $ | (0.82 | ) | $ | (0.67 | ) | $ | (2.32 | ) | $ | (3.09 | ) | ||||
| Weighted average shares used in computing net loss per share attributable to common stockholders—basic and diluted | 48,963 | 41,838 | 47,881 | 37,463 | ||||||||||||
Twist Bioscience Corporation
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands)
| June 30, 2021 | September 30, 2020 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 475,279 | $ | 93,667 | ||||
| Short-term investments | 44,129 | 196,335 | ||||||
| Accounts receivable, net | 28,116 | 26,376 | ||||||
| Inventories | 21,224 | 12,289 | ||||||
| Prepaid expenses and other current assets | 7,859 | 6,203 | ||||||
| Total current assets | 576,607 | 334,870 | ||||||
| Property and equipment, net | 37,864 | 25,466 | ||||||
| Operating lease right-of-use assets | 62,803 | 33,699 | ||||||
| Other non-current assets | 48,024 | 4,847 | ||||||
| Total assets | $ | 725,298 | $ | 398,882 | ||||
| Current liabilities | ||||||||
| Accounts payable | $ | 11,268 | $ | 4,830 | ||||
| Accrued liabilities | 24,390 | 18,846 | ||||||
| Current portion of long-term debt | 7,545 | 3,333 | ||||||
| Current portion of operating lease liabilities | 2,365 | 6,409 | ||||||
| Other current liabilities | 9,265 | 2,611 | ||||||
| Total current liabilities | 54,833 | 36,029 | ||||||
| Operating lease liabilities, net of current portion | 53,849 | 24,837 | ||||||
| Long-term debt, net of current portion | - | 1,403 | ||||||
| Other non-current liabilities | 6,168 | 351 | ||||||
| Total liabilities | 114,850 | 62,620 | ||||||
| Total stockholders’ equity | $ | 610,448 | $ | 336,262 | ||||
| Total liabilities and stockholders’ equity | $ | 725,298 | $ | 398,882 | ||||